The study of the treatment efficacy in prostate cancer with low dose abiraterone
Completed
- Conditions
- Prostate cancer
- Registration Number
- TCTR20211012001
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Male
- Target Recruitment
- 21
Inclusion Criteria
1. Metastatic prostate cancer patients who are not previously received chemotherapy.
2. Patients agree to consent for the study.
3. ECOG performance status 0-2
Exclusion Criteria
1. Patient who has prior treatment with abiraterone or enzalutamide.
2. Patient who has received treatment with drug or other procedure such as
radiation therapy and radionuclear Radium 223 method.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Survival time Aug 2019 - July 2020 observational and comparative design
- Secondary Outcome Measures
Name Time Method Progression free survival Aug 2019 - July 2020 observational and comparative design,Quality of life Aug 2019 - July 2020 observational and comparative design,PSA response Aug 2019 - July 2020 observational and comparative design